Dovitus - Company finances
- The company has not submitted financial data for these years: 2021.
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 0 | 520 | 4,692 | 77,284 |
| Profit before tax | 0 | 0 | -18 | -1,198 | 5,969 |
| Net profit | 0 | 0 | -18 | -1,198 | 5,611 |
| Equity | 0 | 0 | -18 | -1,198 | 4,413 |
| Liabilities | - | 0 | 0 | 0 | 3,478 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 0 | 0 | -18 | -1,198 | 7,891 |
| Total assets | 0 | 0 | -18 | -1,198 | 7,891 |
|
Taxes paid
|
|||||
| STI taxes | - | - | - | - | 6,877 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | - | +802.3% | +1547.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | 71.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | 127.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | -3.5% | -25.5% | 7.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | -3.5% | -25.5% | 7.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Dovitus - Social security debts
The company had no debts to Sodra
Dovitus - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Dovitus is: 9 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 8.88 |
| 2026-08-31 | 2026-08-31 | 7.41 |
| 2025-10-30 | 2025-10-30 | 519.72 |
| 2025-10-26 | 2025-10-29 | 857.58 |
| 2025-10-23 | 2025-10-25 | 1290.69 |
| 2025-10-22 | 2025-10-22 | 1538.8 |
| 2025-10-21 | 2025-10-21 | 1785.4 |
| 2025-10-20 | 2025-10-20 | 1841.16 |
| 2025-10-16 | 2025-10-19 | 1839.18 |
| 2025-10-02 | 2025-10-15 | 2503.32 |
| 2025-09-30 | 2025-10-01 | 2605.25 |
| 2025-09-28 | 2025-09-29 | 2602.57 |
| 2025-09-26 | 2025-09-27 | 2684.33 |
| 2025-09-25 | 2025-09-25 | 2683.65 |
| 2025-09-14 | 2025-09-24 | 2669.85 |
| 2025-09-09 | 2025-09-13 | 2700.7 |
| 2025-09-05 | 2025-09-08 | 2794.4 |
| 2025-09-02 | 2025-09-04 | 2791.51 |
| 2025-09-01 | 2025-09-01 | 2827.09 |
| 2025-08-31 | 2025-08-31 | 2825.63 |
| 2025-08-28 | 2025-08-30 | 2898.75 |
| 2025-08-27 | 2025-08-27 | 1654.43 |
| 2025-08-25 | 2025-08-26 | 1848.04 |
| 2025-08-24 | 2025-08-24 | 1837.0 |
| 2025-08-23 | 2025-08-23 | 1834.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Dovitus, MB (code 303342019) is a Small partnership engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €77.3K and net profit of €5.6K, corresponding to a profit margin of 7.3%. This marks a strong improvement from 2024, when revenue was €4.7K and the company recorded a net loss of €1.2K, after a near-breakeven 2023 with €520 in revenue and an €18 loss. Revenue growth in 2025 was exceptionally strong versus both 2024 and 2023, reflecting a clear change in scale. At year-end 2025, total assets stood at €7.9K, equity at €4.4K, and liabilities at €3.5K, indicating a moderate leverage position. Key ratios were also strong, with ROE at 127.2%, ROA at 71.1%, debt-to-equity at 0.79, and asset turnover at 9.79x. No staff data was provided, so revenue per employee cannot be assessed.